Adoptive regulatory T cell therapy: challenges in clinical transplantation

Niloufar Safinia; Pervinder Sagoo; Robert Lechler; Giovanna Lombardi

doi:10.1097/MOT.0b013e32833bfadc

Adoptive regulatory T cell therapy: challenges in clinical transplantation

Niloufar Safinia, Pervinder Sagoo, Robert Lechler, Giovanna Lombardi

Research output: Contribution to journal › Literature review › peer-review

35 Citations (Scopus)

Abstract

Purpose of review The identification and characterisation of regulatory T cells (Tregs) has recently opened up exciting opportunities for Treg cell therapy in transplantation. In this review, we outline the basic biology of Tregs and discuss recent advances and challenges for the identification, isolation and expansion of these cells for cell therapy. Recent findings Tregs of thymic origin have been shown to be key regulators of immune responses in mice and humans, preventing autoimmunity, graft-versus-host disease and organ graft rejection in the transplantation setting. To date, a variety of different methods to isolate and expand Tregs ex vivo have been advocated. Although promising, relatively few clinical trials of human Treg cell infusion have been initiated. Summary Many key questions about Treg cell therapy still remain and here we provide an in-depth analysis and highlight the challenges and opportunities for immune intervention with Treg-based therapeutics in clinical transplantation.

Original language	English
Pages (from-to)	427 - 434
Number of pages	8
Journal	Current Opinion in Organ Transplantation
Volume	15
Issue number	4
DOIs	https://doi.org/10.1097/MOT.0b013e32833bfadc
Publication status	Published - Aug 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/MOT.0b013e32833bfadc

Cite this

@article{5014ca76e0e64597a62df0c7cb44be53,

title = "Adoptive regulatory T cell therapy: challenges in clinical transplantation",

abstract = "Purpose of review The identification and characterisation of regulatory T cells (Tregs) has recently opened up exciting opportunities for Treg cell therapy in transplantation. In this review, we outline the basic biology of Tregs and discuss recent advances and challenges for the identification, isolation and expansion of these cells for cell therapy. Recent findings Tregs of thymic origin have been shown to be key regulators of immune responses in mice and humans, preventing autoimmunity, graft-versus-host disease and organ graft rejection in the transplantation setting. To date, a variety of different methods to isolate and expand Tregs ex vivo have been advocated. Although promising, relatively few clinical trials of human Treg cell infusion have been initiated. Summary Many key questions about Treg cell therapy still remain and here we provide an in-depth analysis and highlight the challenges and opportunities for immune intervention with Treg-based therapeutics in clinical transplantation.",

author = "Niloufar Safinia and Pervinder Sagoo and Robert Lechler and Giovanna Lombardi",

year = "2010",

month = aug,

doi = "10.1097/MOT.0b013e32833bfadc",

language = "English",

volume = "15",

pages = "427 -- 434",

journal = "Current Opinion in Organ Transplantation",

issn = "1531-7013",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Adoptive regulatory T cell therapy: challenges in clinical transplantation

AU - Safinia, Niloufar

AU - Sagoo, Pervinder

AU - Lechler, Robert

AU - Lombardi, Giovanna

PY - 2010/8

Y1 - 2010/8

N2 - Purpose of review The identification and characterisation of regulatory T cells (Tregs) has recently opened up exciting opportunities for Treg cell therapy in transplantation. In this review, we outline the basic biology of Tregs and discuss recent advances and challenges for the identification, isolation and expansion of these cells for cell therapy. Recent findings Tregs of thymic origin have been shown to be key regulators of immune responses in mice and humans, preventing autoimmunity, graft-versus-host disease and organ graft rejection in the transplantation setting. To date, a variety of different methods to isolate and expand Tregs ex vivo have been advocated. Although promising, relatively few clinical trials of human Treg cell infusion have been initiated. Summary Many key questions about Treg cell therapy still remain and here we provide an in-depth analysis and highlight the challenges and opportunities for immune intervention with Treg-based therapeutics in clinical transplantation.

AB - Purpose of review The identification and characterisation of regulatory T cells (Tregs) has recently opened up exciting opportunities for Treg cell therapy in transplantation. In this review, we outline the basic biology of Tregs and discuss recent advances and challenges for the identification, isolation and expansion of these cells for cell therapy. Recent findings Tregs of thymic origin have been shown to be key regulators of immune responses in mice and humans, preventing autoimmunity, graft-versus-host disease and organ graft rejection in the transplantation setting. To date, a variety of different methods to isolate and expand Tregs ex vivo have been advocated. Although promising, relatively few clinical trials of human Treg cell infusion have been initiated. Summary Many key questions about Treg cell therapy still remain and here we provide an in-depth analysis and highlight the challenges and opportunities for immune intervention with Treg-based therapeutics in clinical transplantation.

U2 - 10.1097/MOT.0b013e32833bfadc

DO - 10.1097/MOT.0b013e32833bfadc

M3 - Literature review

SN - 1531-7013

VL - 15

SP - 427

EP - 434

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

IS - 4

ER -

Adoptive regulatory T cell therapy: challenges in clinical transplantation

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this